Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$84.7 million.

  • Viridian Therapeutics, Inc.\DE's Free Cash Flow fell 2461.65% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.3 million, marking a year-over-year decrease of 6529.13%. This contributed to the annual value of -$232.8 million for FY2024, which is 2580.78% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Free Cash Flow stood at -$84.7 million for Q3 2025, which was down 2461.65% from -$75.4 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Free Cash Flow peaked at -$11.6 million during Q1 2021, and registered a low of -$92.7 million during Q1 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Free Cash Flow value was -$39.4 million (recorded in 2023), while the average stood at -$43.2 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Free Cash Flow plummeted by 19337.92% in 2023 and then soared by 2736.19% in 2024.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Free Cash Flow stood at -$16.6 million in 2021, then tumbled by 106.23% to -$34.3 million in 2022, then fell by 11.01% to -$38.0 million in 2023, then tumbled by 93.04% to -$73.4 million in 2024, then dropped by 15.37% to -$84.7 million in 2025.
  • Its last three reported values are -$84.7 million in Q3 2025, -$75.4 million for Q2 2025, and -$92.7 million during Q1 2025.